DUBLIN--(BUSINESS WIRE)--The "Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Bruton's Tyrosine Kinase (BTK) Inhibitor pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Bruton's Tyrosine Kinase (BTK) Inhibitor Emerging Drugs Chapters
This segment of the Bruton's Tyrosine Kinase (BTK) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bruton's Tyrosine Kinase (BTK) Inhibitor Emerging Drugs
Tolebrutinib (SAR442168) is a covalent, orally active, irreversible BTK inhibitor that penetrates the central nervous system (CNS). It penetrates the Central Nervous System in order to effectively and safely modulate B-cell function without depleting B-cells. Tolebrutinib is in Phase III clinical studies for the treatment of both relapsing and progressive forms of multiple sclerosis (MS). During neuro-inflammation, the number of B cells in the brain increases, which is thought to play a central role in the pathology of MS and other CNS diseases. This provides the potential of targeting the adaptive and innate immunity in both the periphery and also within the CNS. The drug was originally developed by Principia and later on the company was acquired by Sanofi.
Evobrutinib (M-2951) is an orally administered, irreversible antagonist of BTK which inhibits signal transduction until the protein is naturally degraded. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. Evobrutinib is currently undergoing Phase III clinical trials for the treatment of Multiple Sclerosis.
ICP-022: Beijing InnoCare Pharma Tech
ICP-022 (Orelabrutinib) is an orally available potent BTK inhibitor that irreversibly binds to BTK to induce downstream kinase inactivation and cell death. Orelabrutinib was designed with a single ring at the scaffold center instead of a fused bi-cycle core. BTK, a key kinase in the B cell receptor signaling pathway, plays important roles in the development and function of B cells, macrophages, and microglia, which are involved in the immunopathological characteristics of MS.
LOU064 (Remibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor developed by Novartis. In studies, LOU064 inhibits BTK activity with an IC50 value of 0.023 ?M in blood. The drug is currently in phase II stage of development for the treatment of chronic spontaneous urticarial and Sjogren's syndrome and in Phase I clinical studies for the treatment of Atopic diathesis/Atopic dermatitis.
TG 1701: TG therapeutics
TG-1701 is an investigational oral, once-daily BTK inhibitor that irreversibly binds to and inhibits Bruton's tyrosine kinase (BTK), a crucial driver of B-cell proliferation. B-cell receptor (BCR) signaling drives normal B-cell development and supports the growth and survival of malignant B-cells. Targeting BTK has been validated as an important therapeutic strategy for select B-cell malignancies including CLL and NHL. Phase II clinical trials are being carried by Reistone Biopharma for SHR-1459 in the treatment of Neuromyelitis optica. A phase 1 study evaluating TG-1701 as a single agent alone and in combination with ublituximab and umbralisib in patients with CLL and NHL is ongoing by TG therapeutics.
Bruton's Tyrosine Kinase (BTK) Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different Bruton's Tyrosine Kinase (BTK) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Bruton's Tyrosine Kinase (BTK) Inhibitor
There are approx. 30+ key companies which are developing the Bruton's Tyrosine Kinase (BTK) Inhibitor. The companies which have their Bruton's Tyrosine Kinase (BTK) Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Sanofi.
Bruton's Tyrosine Kinase (BTK) Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bruton's Tyrosine Kinase (BTK) Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bruton's Tyrosine Kinase (BTK) Inhibitor drugs.
- Beijing InnoCare Pharma Tech
- Principia Biopharma
- Sorrento Therapeutics
- Zhejiang DTRM Biopharma
- Merck Sharp & Dohme
- TG therapeutics
- Telios Pharma
- Taiho Pharmaceutical
- Gilead Sciences
- Aptose Biosciences
- Carna Biosciences
- Eli Lilly and Company
- TL 895
- TAS 5315
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mhf4c7